Performance Characteristics of the Abbott BinaxNOW SARS-CoV-2 Antigen Test in Comparison to Real-Time Reverse Transcriptase PCR and Viral Culture in Community Testing Sites during November 2020-Reference-Cited by-同舟云学术

Performance Characteristics of the Abbott BinaxNOW SARS-CoV-2 Antigen Test in Comparison to Real-Time Reverse Transcriptase PCR and Viral Culture in Community Testing Sites during November 2020

Published:2022-01-19 Issue:1 Volume:60 Page:
ISSN:0095-1137
Container-title:Journal of Clinical Microbiology
language:en
Short-container-title:J Clin Microbiol

Author:

Almendares Olivia¹^ORCID,Prince-Guerra Jessica L.¹²^ORCID,Nolen Leisha D.¹,Gunn Jayleen K. L.¹,Dale Ariella P.¹³⁴,Buono Sean A.¹²,Deutsch-Feldman Molly¹⁴,Suppiah Suganthi¹,Hao LiJuan¹,Zeng Yan¹,Stevens Valerie A.¹,Knipe Kristen¹,Pompey Justine¹,Atherstone Christine¹⁴,Bui David P.¹⁴,Powell Tracy¹,Tamin Azaibi¹,Harcourt Jennifer L.¹,Petway Marla¹,Bohannon Caitlin¹,Folster Jennifer M.¹,MacNeil Adam¹,Salerno Reynolds¹,Kuhnert-Tallman Wendi¹,Tate Jacqueline E.¹,Thornburg Natalie¹,Kirking Hannah L.¹,Sheiban Khalilullah⁵,Kudrna Julie⁵,Cullen Theresa⁵,Komatsu Kenneth K.³,Villanueva Julie M.¹,Rose Dale A.¹,Neatherlin John C.¹,Anderson Mark¹,Rota Paul A.¹,Honein Margaret A.¹,Bower William A.¹,

Affiliation:

1. COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, USA

2. Laboratory Leadership Service, Centers for Disease Control and Prevention, Atlanta, Georgia, USA

3. Arizona Department of Health Services, Phoenix, Arizona, USA

4. Epidemic Intelligence Service, Centers for Disease Control and Prevention, Atlanta, Georgia, USA

5. Pima County Health Department, Tucson, Arizona, USA

Abstract

Point-of-care antigen tests are an important tool for SARS-CoV-2 detection. Antigen tests are less sensitive than real-time reverse transcriptase PCR (rRT-PCR).

Funder

HHS | Centers for Disease Control and Prevention

Publisher

American Society for Microbiology

Subject

Microbiology (medical)

Link

https://journals.asm.org/doi/pdf/10.1128/JCM.01742-21

Reference37 articles.

1. U.S. Food and Drug Administration. 2021. In vitro diagnostics EUAs–antigen diagnostic tests for SARS-CoV-2. FDA Silver Spring MD. https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/in-vitro-diagnostics-euas-antigen-diagnostic-tests-sars-cov-2.

2. Abbott Diagnostics. 2020. BinaxNOW COVID-19 Ag card (PN 195–000)—instructions for use. https://www.fda.gov/media/141570/download.

3. CMS. 2020. Updated CLIA SARS-CoV-2 molecular and antigen point of care test enforcement discretion. https://www.cms.gov/files/document/clia-sars-cov-2-point-care-test-enforcement-discretion.pdf.

4. U.S. Food and Drug Administration. 2020. COVID-19 test uses: FAQs on testing for SARS-CoV-2. FDA Silver Spring MD. https://www.fda.gov/medical-devices/coronavirus-covid-19-and-medical-devices/covid-19-test-uses-faqs-testing-sars-cov-2.

5. U.S. Department of Health and Human Services. 2020. Coronavirus (COVID-19) testing: expanding access to coronavirus (COVID-19) testing. https://www.hhs.gov/coronavirus/testing/index.html.

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Diagnostic Accuracy of the Abbott BinaxNOW COVID‐19 Antigen Card Test, Puerto Rico;Influenza and Other Respiratory Viruses;2024-07

2. Test accuracy of rapid diagnostic tests and reverse‐transcription polymerase chain reaction against virus isolation in cell culture for assessing SARS‐CoV‐2 infectivity: Systematic review and meta‐analysis;Reviews in Medical Virology;2024-07

3. SARS-CoV-2 Viral Shedding and Rapid Antigen Test Performance — Respiratory Virus Transmission Network, November 2022–May 2023;MMWR. Morbidity and Mortality Weekly Report;2024-04-25

4. Rapid assays of SARS-CoV-2 virus and noble biosensors by nanomaterials;Nano Convergence;2024-01-08

5. Clinical course and management of COVID-19 in the era of widespread population immunity;Nature Reviews Microbiology;2023-12-19